Prognostic roles of mRNA expression of peroxiredoxins in lung cancer
Received 24 July 2018
Accepted for publication 9 October 2018
Published 27 November 2018 Volume 2018:11 Pages 8381—8388
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Takuya Aoki
Liangyuan Chen,1,2 Chunli Huang,2 Xiaojun Yang,3 Qiuqin Zhang,1 Falin Chen1,2
1Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, People’s Republic of China; 2Department of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China; 3Department of Transfusion Medicine, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China
Background: The peroxiredoxin (PRDX) protein family is involved in cancer cell invasion and metastasis, but its prognostic value in lung cancer remain elusive.
Methods: In this report, we accessed the overall survival (OS) of each individual PRDX mRNA expression through the Kaplan–Meier plotter (KM plotter) database, in which updated gene expression data and survival information include a total of 1,926 lung cancer patients.
Results: Our results indicated that PRDX1 and PRDX2 mRNA expressions were associated with improved OS in all lung cancer patients especially in lung adenocarcinoma patients, whereas PRDX5 and PRDX6 mRNA expressions were associated with poor OS in all lung cancer patients. In addition, the prognostic value of PRDXs in the different clinicopathological features according to smoking status, pathological grades, clinical stages, and chemotherapeutic treatment of lung cancer patients was further assessed in the KM plotter database by the multivariate cox regression analysis.
Conclusion: Our finding will elucidate the prognostic role of PRDXs in lung cancer and might promote development of PRDX-targeted inhibitors for the treatment of lung cancer.
Keywords: PRDX, expression, prognostic, KM plotter, smoking status, lung cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]